Takahiro Amano

Takahiro Amano

Auto-generated profile, based on publicly available information

Takahiro Amano

Department of Gastroenterology Ikeda Municipal Hospital Osaka Japan

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 May 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
YOYuriko Otake-Kasamoto
Yuriko Otake-Kasamoto
HKHisako Kayama
Hisako Kayama
TKToshihiro Kishikawa
Toshihiro Kishikawa
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
TTTaku Tashiro
Taku Tashiro
TTTetsuo Takehara
Tetsuo Takehara
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.

10 March 2021 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
RURyotaro Uema
Ryotaro Uema
YHYoshito Hayashi
Yoshito Hayashi
TTTaku Tashiro
Taku Tashiro
HSHirotsugu Saiki
Hirotsugu Saiki
MKMinoru Kato
Minoru Kato
TTTetsuo Takehara
Tetsuo Takehara

1 January 2011 in Internal Medicine
Verified
Journal Article
Open access
PDF file
YMYoshikazu Mizoi
Yoshikazu Mizoi
TYToshimasa Yamamoto
Toshimasa Yamamoto
NMNarihiro Minami
Narihiro Minami
AOAya Ohkuma
Aya Ohkuma
INIkuya Nonaka
Ikuya Nonaka
NANOBUO ARAKI
NOBUO ARAKI
We report genetically confirmed heterozygote oculopharyngeal muscular dystrophy (OPMD) accompanied by dementia, suggesting a possible causal association between OPMD and dementia. The proband first noticed bilateral ptosis, dysphagia, and proximal dominant muscle weakness in the lower extremities at age 53. Ten years later, she was found to have dementia with a score of 10/30 on the mini-mental state examination (MMSE). On PABPN1 gene analysis, the GCN repeat was expanded 17 times in one allele. In addition, the proband's younger brother exhibited myopathy and dementia. To our knowledge, this is the first report of genetically confirmed heterozygote OPMD associated with dementia.

30 May 2025 in Crohn's & Colitis 360
Verified
Journal Article
Open access
TATakahiro Amano
Takahiro Amano
TYTakeo Yoshihara
Takeo Yoshihara
TNTsutomu Nishida
Tsutomu Nishida
YSYuko Sakakibara
Yuko Sakakibara
TYTakuya Yamada
Takuya Yamada
TTTetsuo Takehara
Tetsuo Takehara
Background: There are currently no standardized guidelines for optimizing 5-aminosalicylic acid (5-ASA) maintenance treatment, particularly in patients with ulcerative colitis (UC) who have achieved clinical remission (CR). Therefore, this study examined the perspectives of patients and physicians regarding 5-ASA dose reduction and medication adherence to optimize maintenance treatment. Methods: This cross-sectional study was conducted from February 2023 to May 2023 at 19 institutions and included patients with UC and physicians. The participants’ perspectives were assessed using an anonymous questionnaire. Results: This study included 369 patients with UC (female, 43.1%; age, > 60 years, 29.3%; CR, 88.9%). Preference to reduce the 5-ASA dose and low medication adherence were observed in 46.1% and 16.0% of patients, respectively. Low medication adherence (odds ratio [OR]: 3.43, 95% confidence interval [CI]: 1.67–7.03) was associated with the preference to reduce the 5-ASA dose. Multivariate analysis for factors associated with low medication adherence revealed age < 60 years (OR: 10.25, 95% CI: 3.58–29.38), no intractable disease subsidy (OR: 2.63, 95% CI: 1.09–6.35), dosing frequency ≥ 2 times/day (OR: 9.04, 95% CI: 3.67–22.25), and preference to reduce the 5-ASA dose (OR: 2.57, 95% CI: 1.16–5.70) as significant. Among 153 physicians, 62.7% had > 10 years of experience, and 51.0% regularly verified adherence, with experience being a significant factor (OR: 2.01, 95% CI: 1.10–3.68). Conclusions: Factors influencing medication adherence with 5-ASA included patients’ desire for dose reduction and physicians’ lack of experience. Improving communication with patients and enhancing education for physicians could help optimize treatment with 5-ASA.

30 April 2025 in Intestinal Research
Verified
Journal Article
Open access
PDF file
TKTaku Kobayashi
Taku Kobayashi
Kei MoriyaKei Moriya
Kei Moriya
TFToshimitsu Fujii
Toshimitsu Fujii
SBShigeki Bamba
Shigeki Bamba
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
THToshifumi Hibi
Toshifumi Hibi
Background/Aims: Bowel urgency is an important symptom for quality of life determination in patients with ulcerative colitis (UC). Few clinical studies have focused on bowel urgency as an efficacy endpoint. Budesonide foam enema has shown efficacy for clinical and endoscopic improvement in mild-to-moderate UC. We evaluated the improvement of clinical symptoms (bowel urgency), safety, and treatment impact of twice-daily budesonide foam enema on the quality of life in patients with UC.Methods: This open-label, multicenter, prospective observational study comprised a 4-week observation period assessing the effectiveness and safety of twice-daily budesonide foam enema. Mild-to-moderate UC patients who had bowel urgency were included. Patients collected data daily in an electronic patient-reported outcome system or logbooks. The primary endpoint was the rate of resolution of bowel urgency at the end of the 4-week observation period. The rate of bowel incontinence was also assessed. Results: Sixty-one patients were enrolled. Of patients with a final evaluation, the rate of resolution of bowel urgency was 58.5% (31/53; 95% confidence interval, 44.1%–71.9%). Bowel urgency decreased over time, with a significant difference observed on day 7 versus day 0. Bowel incontinence showed a decreasing trend from day 5, with a significant difference confirmed on day 12 versus day 0. The clinical remission rate was 64.4% (38/59; 95% confidence interval, 50.9%–76.4%). One adverse event not related to budesonide rectal foam occurred. Conclusions: The findings suggest that bowel urgency can be improved early with twice-daily budesonide foam enema. No new safety signals were observed.

31 October 2025 in Intestinal Research
Verified
Journal Article
Open access
TNTsutomu Nishida
Tsutomu Nishida
TATakahiro Amano
Takahiro Amano
NONaoto Osugi
Naoto Osugi
TYTakeo Yoshihara
Takeo Yoshihara
Comments on “Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey”